Projects per year
Fingerprint
Dive into the research topics where Mark R Litzow is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Finished
-
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML
Cai, S. F., Huang, Y., Lance, J. R., Mao, H. C., Dunbar, A. J., McNulty, S. N., Druley, T., Li, Y., Baer, M. R., Stock, W., Kovacsovics, T., Blum, W. G., Schiller, G. J., Olin, R. L., Foran, J. M., Litzow, M., Lin, T., Patel, P., Foster, M. C., Boyiadzis, M., & 18 others , Jan 23 2024, In: Blood Advances. 8, 2, p. 429-440 12 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Building a better blinatumomab
Litzow, M. R., Apr 2024, In: American journal of hematology. 99, 4, p. 512-514 3 p.Research output: Contribution to journal › Editorial › peer-review
-
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant
Tefferi, A., Pardanani, A., Begna, K. H., Al-Kali, A., Hogan, W., Litzow, M. R., Ketterling, R. P., Reichard, K. K. & Gangat, N., Dec 2024, In: Blood cancer journal. 14, 1, 51.Research output: Contribution to journal › Letter › peer-review
Open Access -
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents
Johnson, I. M., Karrar, O., Rana, M., Iftikhar, M., Chen, S., McCullough, K., Saliba, A. N., Al-Kali, A., Alkhateeb, H., Begna, K., Litzow, M., Hogan, W. J., Shah, M., Patnaik, M. M., Pardanani, A., Hermann, J., Tefferi, A. & Gangat, N., Apr 2024, In: British journal of haematology. 204, 4, p. 1232-1237 6 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers
Abaza, Y., Winer, E. S., Murthy, G. S. G., Shallis, R. M., Matthews, A. H., Badar, T., Geramita, E. M., Kota, V. K., Swaroop, A., Doukas, P., Bradshaw, D., Helenowski, I. B., Liu, Y., Zhang, H., Im, A., Litzow, M. R., Perl, A. E., Atallah, E. & Altman, J. K., Apr 2024, In: American journal of hematology. 99, 4, p. 606-614 9 p.Research output: Contribution to journal › Article › peer-review
Open Access